April 2023 tender notification - CORRECTION (29 JUNE 2023)
Pharmac is pleased to provide the latest tender results
Download the tender notification [PDF 58 KB]
Tender results
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2022/23 Invitation to Tender, dated 31 October 2022.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 May 2023 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
__________________________________________________________________________________
CORRECTIONS TO APRIL 2023 TENDER NOTIFICATION
- The incorrect dose for ‘Metoprolol succinate - Tab long-acting 190 mg; 90 tablet blister pack’
- The incorrect price for ‘Metoprolol succinate - Tab long-acting 47.5 mg to $3.65’ in both Section B and Section H.
Corrections in bold and strikethrough below.
2022/23 Tender – Principal Supply Status applies until 30 June 2026
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Bisoprolol fumarate |
Tab 2.5 mg; 90 tablet bottle pack |
$1.84 |
$1.36 |
Ipca-Bisoprolol (Miro) |
1 November 2023 |
1 April 2024 |
Bisprolol Mylan (Viatris) Bisprolol Viatris (Viatris) |
|
Bisoprolol fumarate |
Tab 5 mg; 90 tablet bottle pack |
$2.55 |
$1.91 |
Ipca-Bisoprolol (Miro) |
1 November 2023 |
1 April 2024 |
Bisprolol Mylan (Viatris) Bisprolol Viatris (Viatris) |
|
Bisoprolol fumarate |
Tab 10 mg; 90 tablet bottle pack |
$3.62 |
$2.71 |
Ipca-Bisoprolol (Miro) |
1 November 2023 |
1 April 2024 |
Bisprolol Mylan (Viatris) Bisprolol Viatris (Viatris) |
|
Captopril |
Oral liquid 5 mg per ml; 100 ml bottle OP |
$94.99 (per 95 ml) |
$86.00 |
DP-Captopril (Douglas) |
1 November 2023 |
1 April 2024 |
Capoten (Arrow) |
|
Escitalopram |
Tab 10 mg; 28 tablet blister pack |
$1.07 |
$0.79 |
Ipca-Escitalopram (Miro) |
1 November 2023 |
1 April 2024 |
Escitalopram (Ethics) (Multichem) |
|
Escitalopram |
Tab 20 mg; 28 tablet blister pack |
$1.92 |
$1.49 |
Ipca-Escitalopram (Miro) |
1 November 2023 |
1 April 2024 |
Escitalopram (Ethics) (Multichem) |
|
Metoprolol succinate |
Tab long-acting 23.75 mg; 90 tablet blister pack |
$1.45 (30 tab pack) |
$4.20 |
Myloc CR (Viatris) |
1 November 2023 |
1 April 2024 |
Betaloc CR (AstraZeneca) |
|
Metoprolol succinate |
Tab long-acting 47.5 mg; 90 tablet blister pack |
$1.43 (30 tab pack) |
$3.56 $3.65 |
Myloc CR (Viatris) |
1 November 2023 |
1 April 2024 |
Betaloc CR (AstraZeneca) |
|
Metoprolol succinate |
Tab long-acting 95 mg; 90 tablet blister pack |
$2.15 (30 tab pack) |
$5.24 |
Myloc CR (Viatris) |
1 November 2023 |
1 April 2024 |
Betaloc CR (AstraZeneca) |
|
Metoprolol succinate |
Tab long-acting 195 190 mg; 90 tablet blister pack |
$4.27 (30 tab pack) |
$9.76 |
Myloc CR (Viatris) |
1 November 2023 |
1 April 2024 |
Betaloc CR (AstraZeneca) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Bisoprolol fumarate |
Tab 2.5 mg; 90 tablet bottle pack |
$1.84 |
$1.36 |
Ipca-Bisoprolol (Miro) |
5% |
1 November 2023 |
1 April 2024 |
Bisprolol Mylan (Viatris) Bisprolol Viatris (Viatris) |
|
Bisoprolol fumarate |
Tab 5 mg; 90 tablet bottle pack |
$2.55 |
$1.91 |
Ipca-Bisoprolol (Miro) |
5% |
1 November 2023 |
1 April 2024 |
Bisprolol Mylan (Viatris) Bisprolol Viatris (Viatris) |
|
Bisoprolol fumarate |
Tab 10 mg; 90 tablet bottle pack |
$3.62 |
$2.71 |
Ipca-Bisoprolol (Miro) |
5% |
1 November 2023 |
1 April 2024 |
Bisprolol Mylan (Viatris) Bisprolol Viatris (Viatris) |
|
Ceftazidime |
Inj 1 g vial; 10 vial pack |
$2.69 (per 1 vial pack) |
$25.80 |
Ceftazidime Kabi (Fresenius Kabi) |
5% |
1 July 2023 |
1 December 2023 |
Ceftazidime-AFT (AFT) |
|
Captopril |
Oral liquid 5 mg per ml; 100 ml bottle |
$94.99 (per 95 ml) |
$86.00 |
DP-Captopril (Douglas) |
5% |
1 November 2023 |
1 April 2024 |
Capoten (Arrow) |
|
Escitalopram |
Tab 10 mg; 28 tablet blister pack |
$1.07 |
$0.79 |
Ipca-Escitalopram (Miro) |
5% |
1 November 2023 |
1 April 2024 |
Escitalopram (Ethics) (Multichem) |
|
Escitalopram |
Tab 20 mg; 28 tablet blister pack |
$1.92 |
$1.49 |
Ipca-Escitalopram (Miro) |
5% |
1 November 2023 |
1 April 2024 |
Escitalopram (Ethics) (Multichem) |
|
Metoprolol succinate |
Tab long-acting 23.75 mg; 90 tablet blister pack |
$1.45 (30 tab pack) |
$4.20 |
Myloc CR (Viatris) |
5% |
1 November 2023 |
1 April 2024 |
Betaloc CR (AstraZeneca) |
|
Metoprolol succinate |
Tab long-acting 47.5 mg; 90 tablet blister pack |
$1.43 (30 tab pack) |
$3.56 $3.65 |
Myloc CR (Viatris) |
5% |
1 November 2023 |
1 April 2024 |
Betaloc CR (AstraZeneca) |
|
Metoprolol succinate |
Tab long-acting 95 mg; 90 tablet blister pack |
$2.15 (30 tab pack) |
$5.24 |
Myloc CR (Viatris) |
5% |
1 November 2023 |
1 April 2024 |
Betaloc CR (AstraZeneca) |
|
Metoprolol succinate |
Tab long-acting 195 190 mg; 90 tablet blister pack |
$4.27 (30 tab pack) |
$9.76 |
Myloc CR (Viatris) |
5% |
1 November 2023 |
1 April 2024 |
Betaloc CR (AstraZeneca) |
Tender declines - Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2022/23 Invitation to Tender, dated 31 October 2022.
|
Chemical name |
Line item |
|---|---|
|
Bupivacaine hydrochloride |
inj 2.5 mg per ml, 100 ml bag |
|
Colistin sulphomethate |
inj 150 mg |
|
Etoposide |
cap 50 mg |
|
Etoposide |
cap 100 mg |
|
Etoposide phosphate |
inj 100 mg (of etoposide base) |
|
Permethrin (combined market) |
crm 5% |
|
Permethrin (split market) |
crm 5% |
For products included in the 2020/21, 2021/22 and 2022/2023 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.